New · Papercurve v3

Your documents,
ready to answer back.

Papercurve v3 brings Paige Intelligence into every document. Ask a question and get a cited answer. Run a first-pass regulatory review before a human ever opens the file. Compare versions side by side. All inside the review workflow your team already uses.

Book a discovery call → See what's new ↓
PAGE 14 OF 42
Product Monograph — Corvalen™ (ravitinib)
PART I · HEALTH PROFESSIONAL INFORMATION

4.2 Recommended dose and dosage adjustment

The recommended starting dose of Corvalen is 150 mg orally once daily, taken at approximately the same time each day, with or without food. Treatment should continue until disease progression or unacceptable toxicity.

4.3 Dose modification

For Grade 3 hepatotoxicity, withhold Corvalen until recovery to Grade ≤1, then resume at 100 mg once daily. Permanently discontinue for Grade 4 events or recurrence of Grade 3 after dose reduction.

Dose adjustment is not required for patients with mild renal impairment. Patients with moderate or severe renal impairment were not studied.

1 2
Ask Paige
Document · Corvalen PM
What's the starting dose, and what happens if a patient has Grade 3 liver toxicity?

The recommended starting dose is 150 mg orally once daily, with or without food, at about the same time each day.1

For Grade 3 hepatotoxicity, treatment should be withheld until recovery to Grade ≤1, then resumed at a reduced dose of 100 mg once daily. It should be permanently discontinued for Grade 4 events or if Grade 3 recurs after the reduction.2

p.14 · 4.2 Recommended dose p.14 · 4.3 Dose modification
What's new in v3

Three things your team
can do today.

Every answer is grounded in your own documents, cites the exact page, and leaves the decision with your reviewers.

01 / ASK PAIGE
Chat with any document
Summarise a monograph, find where a claim is supported, or explain a chart. Every answer cites the page it came from, and clicking a citation takes you there.
02 / ASK PAIGE ON LIBRARIES
Chat with a whole library
Ask once across every document in a library. Paige finds the right pages in the right documents and answers with citations to each.
03 / PAIGE REVIEW
First-pass regulatory review
Check a piece against PAAB, FDA warning letters, or 21 CFR 809.10 before it reaches a human reviewer. Findings are tied to a page and location with a recommendation.
02 / Ask Paige on Libraries
Clinical References — Oncology 38 DOCUMENTS
Corvalen Product Monograph (2026-03)p.22
ASCENT-3 Phase III publication — NEJMp.7
ASCENT-3 supplementary appendixp.31
Corvalen HCP detail aid — approved
Investigator brochure v9
Health Canada NOC letter
Ask Paige
Library · 38 documents
Which source supports the 42% reduction in risk of progression, and is the number consistent across our references?

The 42% figure comes from the ASCENT-3 primary analysis (HR 0.58, 95% CI 0.47–0.71) reported in the NEJM publication.1 The Product Monograph cites the same hazard ratio in section 14 Clinical Trials.2

One inconsistency: the supplementary appendix reports the updated 24-month analysis at 39% (HR 0.61), so a piece citing 42% should reference the primary analysis specifically.3

NEJM · p.7 Monograph · p.22 Appendix · p.31
03 / Paige Review · PAAB
Paige Review
Critical · p.1 · main headline
CRITICAL PAAB Code 2.4
Fair balance of risk and benefit
The headline "85% Symptom Reduction!" and subheadline "Fast. Effective. Life-Changing." are in much larger type than the safety information, which is confined to a 6-point footer.
Recommendation Give risk information comparable visual prominence to benefit claims: similar type size, placement in the main body rather than the footer, and reasonable space for safety information.
WONDERDRUG™
(miraclizumab) 100mg injection
85% Symptom Reduction!
Fast. Effective. Life-Changing.
Key Benefits:
✓ 85% of patients achieved symptom reduction
✓ Works in as little as 2 weeks
✓ Once-monthly convenient dosing
Important safety information: Serious infections, malignancies, and hypersensitivity reactions have been reported. See full prescribing information.
Regulatory rules, integrated

One review engine.
Any regulatory code.

Paige Review reads text, charts, imagery, and layout together, then checks what it sees against the rules that apply to your market. A national advertising code, a body of enforcement letters, or a specific labelling regulation all plug into the same engine and surface in the same review panel.

Canada
PAAB
Fair balance, absolute claims, chart and data presentation standards, product monograph disclosure. Reads the piece the way PAAB does.
Code of Advertising Acceptance
United States
FDA / OPDP
Rules traced to real warning letters, so every check reflects an actual enforcement action. Risk balance, indication and efficacy validation, presence checks.
Warning letters
United States · Devices
FDA 21 CFR 809.10
Detects IVD and RUO products in copy and photographs, verifies the required footer on every page, and escalates what it can't confirm to human review.
IVD / RUO labelling
Also in v3

Smaller changes your reviewers
will notice every day.

Version Compare · rebuilt
See exactly what changed between versions.
True side-by-side compare with synced scrolling and zoom. Word-level highlights show what was removed and what was added, and a changes sidebar lets reviewers jump straight to each edit. Switch versions or swap sides without leaving the page.
v4 · Mar 12 ⇄ v5 · Mar 19SYNC SCROLL · SYNC ZOOM
In the ASCENT-3 trial, Corvalen reduced the risk of disease progression or death by 42% versus placebo. Patients received 150 mg once daily for up to 24 months. The most common adverse reactions were fatigue, nausea, and rash.
In the ASCENT-3 trial, Corvalen reduced the risk of disease progression or death by 42% (HR 0.58; 95% CI 0.47–0.71) versus placebo. Patients received 150 mg once daily until progression or unacceptable toxicity. The most common adverse reactions were fatigue, nausea, and diarrhea.
3 CHANGES← PREVNEXT →
01
Every format, one viewer
Word, PowerPoint, images, and PDFs all open the same way. Non-PDF uploads are prepared automatically after upload, and the viewer loads the moment they're ready.
02
Citations you can click
Every Ask Paige answer and every Paige Review finding points to a page and a location. One click takes the reviewer to the exact spot in the document.
03
Conversations that persist
Ask Paige sessions are saved per user and titled automatically, so a question asked during review is still there when the next version arrives.
Built for regulated industries

Your content stays yours.

Papercurve has been purpose-built for life sciences since 2019. Data handling isn't an afterthought. It's the foundation.

✓
Answers come only from your documents
Paige answers from the pages in your document or library and cites each one. If it isn't in your content, Paige doesn't invent it.
✓
No cross-client training
Your Paige instance works from your team's content only. No client data is ever used to serve another customer.
✓
Human-in-the-loop, always
Paige surfaces findings for your reviewers to decide on. Final approval authority stays with your team, never with the AI.
The numbers

Reviews that used to take weeks
now take days.

60%
Reduction in MLR review time across customer deployments.
10×
Faster reference linking with Paige auto-match.
36%
Improvement in time to "everyone approved" with adaptive learning.
Ready to see v3

Let's walk through it
with your content.

A 20-minute call. Bring a piece you're working on and we'll show you Ask Paige and Paige Review running against it. No prep required.

Book a discovery call →